Poll

Poll: What do you consider the optimal approach for treating high-risk prostate cancer?

External beam RT with androgen deprivation therapy
Radical prostatectomy with pelvic lymph node dissection
Neoadjuvant treatment with chemotherapy or ADT
Other
Not sure
Related Videos
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Geoffrey Sonn, MD, on an AI risk mapping tool to predict seminal vesicle invasion
Prostate cancer screening: Expert weighs in after Biden's diagnosis
Prostate cancer screening: Expert weighs in after Biden's diagnosis
1 expert in this video
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
1 expert in this video
Post Hoc Analysis of ARANOTE; Ultra-Low PSA Responses
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Study results affirm effectiveness of evolving prostate cancer therapies
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Rebecca A. Campbell, MD, answers a question during a Zoom video interview
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
1 expert in this video
Comparing Trials Studying Treatment Intensification In mHSPC
An Overview of the ARANOTE Trial
An Overview of the ARANOTE Trial
Related Content
FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
May 21st 2025

FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

Hannah Clarke
The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
May 20th 2025

Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

Hannah Clarke
The phase 3 study design will now be submitted for final review by the agency.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
SBRT may offer a safe alternative to CFRT after prostatectomy
May 16th 2025

SBRT may offer a safe alternative to CFRT after prostatectomy

Hannah Clarke
Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
May 15th 2025

Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

Tracey L. Krupski, MD Jeunice Owens-Walton, MD
"The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
© 2025 MJH Life Sciences

All rights reserved.